Available IPD datapackage for study 'A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive'

Name: Available IPD datapackage for study 'A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive'
Creator: Vivli
Published: 2025-02-10 16:22:15
License: 暂无描述

DataCite Commons2025-02-10 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/dataPackages/PR00007536.0

下载链接

链接失效反馈

官方服务：

资源简介：

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

提供机构：

Vivli

创建时间：

2025-01-03